Our Work

Results from dQ&A Patient Voice Q1 2025 Update

Given that T1D patients share many of the same comorbidities as T2D patients, doctors have been prescribing them to T1D patients ‘off label’.

This study examines how patient trust in AID systems correlates with the perceived effectiveness of the system and how they alleviate diabetes management burdens.

This study assesses how third-party digital health apps (those not specifically tied to a diabetes device) impact glycemic control, mental well-being, and BMI. ‍

This study explores how activity monitoring mobile apps and software impact overall health outcomes in PWT2, focusing on both physical and mental well-being.

dQ&A presented three research abstracts at ATTD 2025, an academic and professional conference of innovation and advancement in diabetes devices. 

People with Type 1 diabetes (PWT1) in Europe (EU) and the United States (USA) generally have similar access to diabetes technologies. So how do their health outcomes compare? dQ&A’s work shows that even with similar treatment plans, differing regional factors influencing diabetes management — such as obesity levels and the cost and accessibility of healthcare — potentially affect patient wellness.

Unreliable respondents are the scourge of consumer panels. Our data shows that cheaters and bots typically represent the majority of commercially available diabetes patient sample. We routinely see them in healthcare provider sample as well.